Stormy Chamberlain is associate professor of genetics and genome sciences and associate director of the Graduate Program in Genetics and Developmental Biology at the University of Connecticut School of Medicine.
Stormy Chamberlain
Associate professor
University of Connecticut
From this contributor
Angelman syndrome’s silent gene points way forward for autism therapies
Advances in research and help from families have brought scientists to the brink of an effective therapy for Angelman syndrome.
Angelman syndrome’s silent gene points way forward for autism therapies
By
Stormy Chamberlain
21 October 2019 | 4 min read
For accurate results in autism, genetic databases need diversity
We must diversify databases of reference DNA to improve our ability to interpret the consequences of genetic variation.
For accurate results in autism, genetic databases need diversity
By
Stormy Chamberlain, Louisa Kalsner
10 April 2018 | 5 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read